A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Recruiting · Phase 1 · NCT06809400
Conditions: Parkinson Disease
At a glance
- Research payments reported, 2025
- $185,015
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4006896 (drug), Placebo (drug)
- Dates
- Started 2025-02-18; completion 2028-10
- Results posted
- Not yet
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $185,015 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Trustees of Columbia Univ in The City of Ny $151,065
- Collaborative Neuroscience Research LLC $33,950
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.